Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 233.80K | 123.10K | 202.50K | 311.40K | 495.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.80K | 123.10K | 202.50K | 311.40K | 495.50K |
| Cost of Revenue | 20.30K | 21.30K | 14.20K | 20.40K | 39.60K |
| Gross Profit | 213.50K | 101.80K | 188.30K | 291.00K | 455.90K |
| SG&A Expenses | 3.01M | 2.24M | 2.45M | 1.78M | 1.75M |
| Depreciation & Amortization | 2.20K | 2.20K | 2.20K | 4.80K | 4.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.52M | 5.76M | 5.31M | 5.95M | 5.26M |
| Operating Income | -8.29M | -5.64M | -5.11M | -5.64M | -4.77M |
| Income Before Tax | -8.83M | -5.98M | -4.34M | -5.64M | -4.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.83M | -5.98M | -4.34M | -5.64M | -4.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.83M | -5.98M | -4.34M | -5.64M | -4.77M |
| EBIT | -8.29M | -5.64M | -5.11M | -5.64M | -4.77M |
| EBITDA | -8.29M | -5.63M | -5.11M | -5.64M | -4.76M |
| EPS Basic | -0.31 | -0.21 | -0.15 | -0.25 | -0.29 |
| Normalized Basic EPS | -0.16 | -0.11 | -0.09 | -0.16 | -0.18 |
| EPS Diluted | -0.31 | -0.21 | -0.15 | -0.25 | -0.29 |
| Normalized Diluted EPS | -0.16 | -0.11 | -0.09 | -0.16 | -0.18 |
| Average Basic Shares Outstanding | 28.73M | 28.64M | 28.59M | 22.13M | 16.19M |
| Average Diluted Shares Outstanding | 28.73M | 28.64M | 28.59M | 22.13M | 16.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
